Androgen deprivation therapy for prostate cancer: Current status and future prospects
Version of Record online: 26 APR 2004
Copyright © 2004 Wiley-Liss, Inc.
Volume 61, Issue 4, pages 332–353, 1 December 2004
How to Cite
Miyamoto, H., Messing, E. M. and Chang, C. (2004), Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate, 61: 332–353. doi: 10.1002/pros.20115
- Issue online: 22 OCT 2004
- Version of Record online: 26 APR 2004
- Manuscript Accepted: 15 JAN 2004
- Manuscript Received: 8 JAN 2004
- George Whipple Professor Endowment
- androgen receptor;
- androgen receptor coregulator;
- androgen-independent prostate cancer;
- antiandrogen withdrawal syndrome
Androgens play a major role in promoting the development and progression of prostate cancer. As a result, androgen ablation or blockade of androgen action through the androgen receptor (AR) has been the cornerstone of treatment of advanced prostate cancer. Different strategies involving this hormonal therapy produce a significant clinical response in most of the patients, but most responders eventually lose dependency, resulting in mortality. Thus, whether hormonal therapy contributes to the improvement of overall survival rates, especially in patients with advanced prostate cancer, remains controversial. However, patients with advanced disease clearly have a benefit from androgen deprivation-based treatment for palliating their symptoms and for improving the quality of their lives. In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified. © 2004 Wiley-Liss, Inc.